Skin contamination by oestradiol gel - A remarkable source of error in plasma oestradiol measurements during percutaneous hormone replacement therapy

Maturitas

Volumn 48, Issue 4, 2004, Pages 347-353

  Vihtamäki, Tarja ^a   Luukkaala, Tiina ^b   Tuimala, Risto ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Blood; Hysterectomized postmenopause; Oestradiol gel

Indexed keywords

ESTRADIOL;

ADULT; ANALYTICAL ERROR; ARM; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTAMINATION; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; GEL; GLOVE; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; SKIN; STATISTICAL SIGNIFICANCE; THIGH;

ADMINISTRATION, CUTANEOUS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; SKIN;

EID: 3342957085     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(03)00043-4     Document Type: Article

References (24)

1. Field C.S., Ory S.J., Wahner H.W., Hermann R.R., Judd H.L., Riggs B.L. Preventive effects of transdermal 17β-estradiol on osteoporotic changes after surgical menopause: a 2-year placebo-controlled trial. Am. J. Obstet. Gynecol. 168:1993;114-121
2. De Ligniers B. Hormone replacement therapy, compliance and individually adapted doses. In: Hormone replacement therapy: standardized or individually adapted doses. London: The Parthenon Publishing Group, 1993:59-67.
3. Reference not provided.
4. Komulainen M., Kroger H., Tuppurainen M.T., Heikkinen A.M., Honkanen R., Saarikoski S. Identification of early postmenopausal women with no bone response to HRT: results of a 5-year clinical trial. Osteoporosis Int. 11:2000;211-218
5. Holst J., Cajander S., Carlström K., Damber M.G., Damber B., Schoultz B. A comparison of liver protein induction in postmenopausal women during oral and percutaneous oestrogen replacement therapy. Br J Obstet Gynecol. 90:1983;355-360
6. Chetkowski R.J., Meldrum D.R., Steingold K.A. Biologic effects of transdermal estradiol. New Engl. J. Med. 314:1986;1615-1620
7. Selby P.L., McGarrigle H.H.G., Peacock M. Comparison on the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonadotropin release, bone turnover and climacteric symptoms in postmenopausal women. Clin. Endocrinol. 30:1989;241-249
8. Guy R., Hadgraft J., Bucks D. Transdermal drug delivery and cutaneous metabolism. Xenobiotica. 17:1987;324-343
9. Vihtamäki T., Tuimala R. Can climacteric women self-adjust therapeutic estrogen doses using symptoms as markers. Maturitas. 28:1998;199-203
10. Studd J., Pornel B., Marton I., et al. Efficacy and acceptability of intranasal 17β-estradiol for menopausal symptoms: randomised dose-response study. Lancet. 353:1999;1574-1578
11. Holst J., Carlström K., Schoultz von B. Serum estrogen levels after topic application of estradiol-17β on two different cutaneous areas. Acta Obstet. Gynecol. Scand. 66:1987;151-152
12. Ranade V. Drug delivery system. Transdermal drug delivery. J. Clin. Pharmacol. 31:1991;401-418
13. Karjalainen A., Heikkinen J., Savolaonen M., Bäckström A.-C., Salinto M., Kesäniemi Y. Metabolic cganges induced by peroral oestrogen and transdermal oestradiol gel therapy. Br. J. Obstet. Gynecol. 104S:1997;38-43
14. O'Conell M.B. Pharmacokinetic and pharmacologic variation between different estrogen products. J. Clin. Pharmacol. 35:1995;18S-24S
15. Chanez J.F., Lignieres B., Marty J.P., Wepierre J. Influence of the size of the area of treatment on percutaneous absorption of estradiol in the rat. Skin Pharmacol. 2:1989;15-21
16. Simon JA, Hodgen GD, Archer DF. Are there significant differences between patch and gel cutaneous estradiol therapy. In: Genazzani AR, Petraglia F, Volpe A, editors. Recent research on gynecological endocrinology. Casterton Hall: Parthenon Publishing, 1988:317-24.
17. Järvinen A., Granander M., Nykanen S., Laine T., Geurts P., Viitanen A. Steady-state pharmacokinetics of oestradiol gel in postmenopausal women: effects of application area and washing. Br J Obstet Gynecol. 104(S):1997;14-18
18. Nilsson B., Holst J., Von Schoultz B. Serum levels of unbound 17β-oestradiol during oral and percutaneous postmenopausal replacement therapy. Br. J. Obstet. Gynecol. 91:1984;1031-1036
19. Fahraeus L., Larsson-Cohn U. Oestrogens, gonadotrophins and SHBG during oral and cutaneous administration of oestradiol-17β to menopausal women. Acta Endocrinol. 101:1982;592-596
20. Scott R.T., Ross B., Anderson C., Archer D.F. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet. Gynecol. 77:1991;758-764
21. Vihtamäki T., Parantainen J., Koivisto A.-M., Metsä-Ketelä T., Tuimala R. Oral ascorbic acid increases plasma oestradiol during postmenopausal hormone replacement therapy. Maturitas. 42:2002;129-135
22. Holst J., Carlström K., von Schoulz B. Serum estrogen levels after topic application of estradiol 17β on two different cutaneous areas. Acta Obstet. Gynecol. Scand. 66:1987;151-152
23. Nilsson B., Holst J., von Schoulz B. Serum levels of unbound 17β-oestradiol during oral and percutaneous postmenopausal replacement therapy. Br. J. Obstet. Gynecol. 91:1984;1031-1036
24. Simon J.A., Leal J., Hodgen G.D. Percutaneous absorption of 17β-estradioll in ovariectomized rhesus monkeys: skin and serum pharmacokinetics. Fertil. Steril. 53:1990;561-565